SEMINAL: A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial

IGNITE: A PHASE II SIGNAL-SEEKING TRIAL OF ADAVOSERTIB TARGETING RECURRENT HIGH GRADE SEROUS OVARIAN CANCER WITH CYCLIN E1 OVER-EXPRESSION WITH AND WITHOUT GENE AMPLIFICATION

EFFICACY AND SAFETY OF AVUTOMETINIB + DEFACTINIB IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER FOLLOWING PRIOR SYSTEMIC THERAPY

A RANDOMIZED, PHASE II/III STUDY OF PEGYLATED-LIPOSOMAL-DOXORUBICIN AND ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED-LIPOSOMAL-DOXORUBICIN, BEVACIZUMAB AND ATEZOLIZUMAB VERSUS PEGYLATED-LIPOSOMAL-DOXORUBICIN AND BEVACIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (NRG-GY009)

SELINEXOR MAINTENANCE FOR PATIENTS WITH TP53WT ADVANCED OR RECURRENT ENDOMETRIAL CANCER: LONG-TERM FOLLOW UP OF EFFICACY AND SAFETY SUBGROUP ANALYSIS OF THE ENGOT-EN5/GOG-3055/SIENDO STUDY

EFFICACY AND SAFETY OF TRASTUZUMAB DERUXTECAN IN PATIENTS WITH HER2-EXPRESSING SOLID TUMORS: RESULTS FROM THE CERVICAL, ENDOMETRIAL, AND OVARIAN CANCER COHORTS OF THE DESTINY-PANTUMOR02 STUDY

FLAMES: RANDOMIZED PHASE 3 TRIAL OF MAINTENANCE SENAPARIB IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER

EFFICACY AND SAFETY RESULTS FROM SKYSCRAPER-04: AN OPEN-LABEL RANDOMIZED PHASE 2 TRIAL OF TIRAGOLUMAB PLUS ATEZOLIZUMAB FOR PD-L1-POSITIVE RECURRENT CERVICAL CANCER

SEMINAL: Pembrolizumab Versus Placebo in Addition to Carboplatin and Paclitaxel for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer: The Phase 3, NRG GY018 Study

SEMINAL: A Phase III double-blind randomized placebo-controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer: the AtTEnd study

MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCERS (EC) AND ASSOCIATION WITH RELAPSE-FREE SURVIVAL (RFS) OUTCOMES: ANCILLARY ANALYSIS OF GOG-0258

SEMINAL: DUO-E/GOG-3041/ENGOT-EN10 TRIAL: CARBOPLATIN/PACLITAXEL+DURVALUMAB FOLLOWED BY MAINTENANCE DURVALUMAB±OLAPARIB AS A FIRST-LINE TREATMENT FOR NEWLY DIAGNOSED ADVANCED OR RECURRENT ENDOMETRIAL CANCER

THE EFFECT OF ROSUVASTATIN COMBINED WITH ORAL MEGESTROL ACETATE ON FERTILITY-PRESERVING TREATMENT IN PATIENTS WITH ATYPICAL ENDOMETRIAL HYPERPLASIA: A PROSPECTIVE, SINGLE-ARM PHASE II STUDY

PHASE 1/2 STUDY OF GALINPEPIMUT-S PLUS PEMBROLIZUMAB COMBINATION IN PATIENTS WITH WT1+ PLATINUM-RESISTANT OVARIAN CANCER IN 2ND/3RD LINE OF THERAPY

EFFICACY OF THE PORCUPINE INHIBITOR ETC-1922159 (ETC-159) PLUS PEMBROLIZUMAB IN MICROSATELLITE STABLE (MSS) OR PROFICIENT MISMATCH REPAIR (PMMR) PLATINUM RESISTANT OVARIAN CARCINOMAS (PROC)